Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells

Tumors are considered to be possible targets of immunotherapy using stimulated and expanded autologous or allogeneic natural killer (NK) cells mismatched for MHC class I molecules and inhibitory NK receptors. NK cell–based immunoadjuvant therapies are carried out in combination with standard chemotherapeutic protocols. In the presented study, we characterized the effect of 28 frequently used chemotherapeutic agents on the capacity of NK cells to kill target cells. We found that treatment of NK cells with the drugs vinblastine, paclitaxel, docetaxel, cladribine, chlorambucil, bortezomib, and MG-132 effectively inhibited NK cell–mediated killing without affecting the viability of NK cells. On the other hand, the following drugs permitted efficient NK cell–mediated killing even at concentrations comparable with or higher than the maximally achieved therapeutic concentration in vivo in humans: asparaginase, bevacizumab, bleomycin, doxorubicin, epirubicin, etoposide, 5-fluorouracil, hydroxyurea, streptozocin, and 6-mercaptopurine. [Mol Cancer Ther 2007;6(2):644–54]

[1]  D. Alberts,et al.  Antitumour activity and plasma kinetics of bleomycin by continuous and intermittent administration. , 1980, British Journal of Cancer.

[2]  U. Tirelli,et al.  Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  E. Gamelin,et al.  Clinical pharmacokinetics of oxaliplatin: a critical review. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  E. Carbone,et al.  Synergistic effect of IFN‐γ and human cytomegalovirus protein UL40 in the HLA‐E‐dependent protection from NK cell‐mediated cytotoxicity , 2001, European journal of immunology.

[5]  J. Ritz,et al.  Biology and clinical relevance of human natural killer cells. , 1990, Blood.

[6]  R. Kiessling,et al.  „Natural”︁ killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell , 1975, European journal of immunology.

[7]  M. A. Sáez,et al.  The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma , 1997, Cancer.

[8]  D. Davis,et al.  The Actin Cytoskeleton Controls the Efficiency of Killer Ig-Like Receptor Accumulation at Inhibitory NK Cell Immune Synapses1 , 2004, The Journal of Immunology.

[9]  A. Chang,et al.  Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. , 1985, The New England journal of medicine.

[10]  M. Smyth,et al.  KHYG-1, a model for the study of enhanced natural killer cell cytotoxicity. , 2005, Experimental hematology.

[11]  G. Trinchieri,et al.  Biology of Natural Killer Cells , 1989, Advances in Immunology.

[12]  A. Boddy,et al.  Intrasubject variation in children of ifosfamide pharmacokinetics and metabolism during repeated administration , 1996, Cancer Chemotherapy and Pharmacology.

[13]  M. Tan,et al.  High‐dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma , 2004, Cancer.

[14]  O. N. Ozes,et al.  Combination treatment of 2-chlorodeoxyadenosine and type I interferon on hairy cell leukemia-like cells: cytotoxic effect and MHC-unrestricted killer cell regulation. , 1993, Blood.

[15]  Klas Kärre,et al.  Spontaneous mutations in the human CMV HLA class I homologue UL18 affect its binding to the inhibitory receptor LIR‐1/ILT2/CD85j , 2006, European journal of immunology.

[16]  R. Goldfarb,et al.  Activation of multiple caspases and modification of cell surface fas (CD95) in proteasome inhibitor‐induced apoptosis of rat natural killer cells , 2003, Journal of cellular biochemistry.

[17]  A. Boddy,et al.  Pharmacokinetics of Dactinomycin in a Pediatric Patient Population: a United Kingdom Children's Cancer Study Group Study , 2005, Clinical Cancer Research.

[18]  H. Klingemann Cellular therapy of cancer with natural killer cells: will it ever work? , 2001, Journal of hematotherapy & stem cell research.

[19]  N. Hanna,et al.  Synergistic antitumor effects of topoisomerase inhibitors and natural cell-mediated cytotoxicity. , 1989, Cancer research.

[20]  M. Caligiuri,et al.  Immunotherapeutic approaches for hematologic malignancies. , 2004, Hematology. American Society of Hematology. Education Program.

[21]  Simon C Watkins,et al.  Nongranular proteolytic enzymes of rat IL‐2–activated natural killer cells. II. Purification and identification of rat A‐NKP 1 and A‐NKP 2 as constituents of the multicatalytic proteinase (proteasome) complex , 1994, Journal of cellular biochemistry.

[22]  H. Kimura,et al.  A Phase III randomized study of interleukin‐2 lymphokine‐activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma , 1997, Cancer.

[23]  R. Danesi,et al.  Gemcitabine, epirubicin and paclitaxel: pharmacokinetic and pharmacodynamic interactions in advanced breast cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Edward J. Lee,et al.  Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  K. Ataga,et al.  The Influence of Renal Function on Hydroxyurea Pharmacokinetics in Adults With Sickle Cell Disease , 2005, Journal of clinical pharmacology.

[26]  M. Björkholm,et al.  Pharmacokinetics of mitoxantrone, etoposide and cytosine arabinoside in leukemic cells during treatment of acute myelogenous leukemia--relationship to treatment outcome and bone marrow toxicity. , 1995, Leukemia research.

[27]  I. Mononen,et al.  Serious Neutropenia in ALL Patients Treated With L-Asparaginase May Be Avoided by Therapeutic Monitoring of the Enzyme Activity in the Circulation , 2002, Therapeutic drug monitoring.

[28]  R. Goldfarb,et al.  Nongranular proteolytic enzymes of rat IL-2-activated natural killer cells. I. Subcellular localization and functional role. , 1992, Journal of immunology.

[29]  S. Clarke,et al.  Phase I and pharmacokinetic study of docetaxel in combination with epirubicin and cyclophosphamide in advanced cancer: dose escalation possible with granulocyte colony-stimulating factor, but not with prophylactic antibiotics. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  M. Martelli,et al.  Natural killer cell alloreactivity for leukemia therapy. , 2005, Journal of immunotherapy.

[31]  P. Katz,et al.  Mechanisms of human cell-mediated cytotoxicity. III. Dependence of natural killing on microtubule and microfilament integrity. , 1982, Journal of immunology.

[32]  R. Gascoyne,et al.  Phase II Study of Oral Vinorelbine in First-Line Advanced Breast Cancer Chemotherapy , 2003 .

[33]  M. Hanada,et al.  Cellular immunosuppression in children with acute lymphoblastic leukemia: Effect of consolidation chemotherapy , 2005, Cancer Immunology, Immunotherapy.

[34]  Lewis L Lanier,et al.  NK cell recognition. , 2005, Annual review of immunology.

[35]  R. Goldfarb,et al.  Non-granular proteolytic enzymes of rat interleukin-2-activated natural killer cells. III. Enhancement of A-NKP 1, 2, and 3 proteolytic activities (cleaving after Arg, Phe and Pro) in response to interleukin-2. , 1995, Natural immunity.

[36]  R. Shanks,et al.  Can severe vincristine neurotoxicity be prevented? , 2004, Cancer Chemotherapy and Pharmacology.

[37]  R. Millikan,et al.  Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  B. Comin-Anduix,et al.  Immunosensitization of Tumor Cells to Dendritic Cell-Activated Immune Responses with the Proteasome Inhibitor Bortezomib (PS-341, Velcade)1 , 2006, The Journal of Immunology.

[39]  R. Goldfarb,et al.  Accumulation of adoptively transferred A-NK cells in murine metastases: kinetics and role of interleukin-2. , 1994, In vivo.

[40]  Adelheid Cerwenka,et al.  Natural killer cells, viruses and cancer , 2001, Nature Reviews Immunology.

[41]  S. Eksborg,et al.  Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex , 2004, Cancer Chemotherapy and Pharmacology.

[42]  S. Natsugoe,et al.  Prognostic value of intratumoral natural killer cells in gastric carcinoma , 2000, Cancer.

[43]  S. Gruber,et al.  Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine , 2004, European Journal of Clinical Pharmacology.

[44]  G. Juliusson,et al.  Pharmacokinetics of cladribine in plasma and its 5'-monophosphate and 5'-triphosphate in leukemic cells of patients with chronic lymphocytic leukemia. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  J. Verweij,et al.  A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin) , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[46]  J. Mcgregor,et al.  Human tumor cell line resistance to chemotherapeutic agents does not predict resistance to natural killer or lymphokine-activated killer cell-mediated cytolysis. , 1990, Cancer research.

[47]  Roberto Canaparo,et al.  Plasma concentrations of 5-fluorouracil and its metabolites in colon cancer patients. , 2004, Pharmacological research.

[48]  L. Moretta,et al.  Killer immunoglobulin-like receptors. , 2004, Current opinion in immunology.

[49]  Hein Putter,et al.  Down-Regulation of HLA-A Expression Correlates with a Better Prognosis in Colorectal Cancer Patients , 2002, Laboratory Investigation.

[50]  S. Steinberg,et al.  A Phase I/II Study of Infusional Vinblastine with the P-Glycoprotein Antagonist Valspodar (PSC 833) in Renal Cell Carcinoma , 2004, Clinical Cancer Research.

[51]  E. Kimby,et al.  Pharmacogenetics of cyclophosphamide in patients with hematological malignancies. , 2006, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[52]  A. Viel,et al.  High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. , 1999, The American journal of pathology.

[53]  Daniel J Weisdorf,et al.  Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor. , 2002, Blood.

[54]  M. Caligiuri,et al.  New developments in anti-tumor efficacy and malignant transformation of human natural killer cells , 2003, Current opinion in hematology.

[55]  C. Le,et al.  Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer. , 2005, Blood.

[56]  D. Newell,et al.  A single-sample assay for the estimation of the area under the free carboplatin plasma concentration versus time curve , 2009, Cancer Chemotherapy and Pharmacology.

[57]  M. Caligiuri,et al.  Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing , 1998, Cancer Immunology, Immunotherapy.

[58]  R. Hubbard,et al.  Lymphocyte subset infiltration patterns and HLA antigen status in colorectal carcinomas and adenomas. , 1996, Gut.

[59]  T. Delozier,et al.  Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.